Paper39607486
Chidamide and venetoclax synergistically regulate the Wnt/β-catenin pathway by MYCN/DKK3 in B-ALL.
Zhao L and 9 others. Ann Hematol, 2025. Cited by 3 papers, by iCite.
Cite this record
ConductScience Library. Chidamide and venetoclax synergistically regulate the Wnt/β-catenin pathway by MYCN/DKK3 in B-ALL. Papers, record 39607486. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39607486
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Chidamide and venetoclax synergistically regulate the Wnt/β-catenin pathway by MYCN/DKK3 in B-ALL.
- PubMed
Topics17
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Bridged Bicyclo Compounds, Heterocyclic | Major topic |
| Aminopyridines | Major topic |
| N-Myc Proto-Oncogene Protein | Major topic |
| Wnt Signaling Pathway | Major topic |
| Sulfonamides | Major topic |
| Benzamides | Major topic |
| Adaptor Proteins, Signal Transducing | Major topic |
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Major topic |
| Intercellular Signaling Peptides and Proteins | Major topic |
| Humans | |
| Animals | |
| Drug Synergism | |
| Mice | |
| Cell Line, Tumor | |
| Antineoplastic Combined Chemotherapy Protocols | |
| Histone Deacetylase Inhibitors | |
| beta Catenin |
Source PubMed
References43
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 21941284 | A decade of exploring the cancer epigenome - biological and translational implications. | Nat Rev Cancer | 2011 | https://conductscience.org/library/papers/21941284 | PubMed |
| 2 | 33691573 | Venetoclax with chemotherapy in relapse/refractory early T-cell precursor acute lymphoblastic leukemia. | Leuk Lymphoma | 2021 | https://conductscience.org/library/papers/33691573 | PubMed |
| 3 | 28604239 | Continuing challenges and current issues in acute lymphoblastic leukemia. | Leuk Lymphoma | 2018 | https://conductscience.org/library/papers/28604239 | PubMed |
| 4 | 27343252 | Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia. | Blood | 2016 | https://conductscience.org/library/papers/27343252 | PubMed |
| 5 | 22682243 | Wnt/β-catenin signaling and disease. | Cell | 2012 | https://conductscience.org/library/papers/22682243 | PubMed |
| 6 | 33160401 | Epigenetic alterations and advancement of treatment in peripheral T-cell lymphoma. | Clin Epigenetics | 2020 | https://conductscience.org/library/papers/33160401 | PubMed |
| 7 | 33566253 | Histone deacetylase inhibitor chidamide regulates the Wnt/β-catenin pathway by MYCN/DKK3 in B-ALL. | Invest New Drugs | 2021 | https://conductscience.org/library/papers/33566253 | PubMed |
| 8 | 26766585 | Parsing Myc Paralogs in Oncogenesis. | Cancer Cell | 2016 | https://conductscience.org/library/papers/26766585 | PubMed |
| 9 | 27194046 | Epigenetic Determinants of Cancer. | Cold Spring Harb Perspect Biol | 2016 | https://conductscience.org/library/papers/27194046 | PubMed |
| 10 | 31974619 | Chidamide induces necroptosis via regulation of c‑FLIPL expression in Jurkat and HUT‑78 cells. | Mol Med Rep | 2020 | https://conductscience.org/library/papers/31974619 | PubMed |
| 11 | 32035785 | Clinical Experience With Venetoclax Combined With Chemotherapy for Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia. | Clin Lymphoma Myeloma Leuk | 2020 | https://conductscience.org/library/papers/32035785 | PubMed |
| 12 | 24334727 | MYCN is a novel oncogenic target in pediatric T-cell acute lymphoblastic leukemia. | Oncotarget | 2014 | https://conductscience.org/library/papers/24334727 | PubMed |
| 13 | 25384499 | Chidamide, a histone deacetylase inhibitor, functions as a tumor inhibitor by modulating the ratio of Bax/Bcl-2 and P21 in pancreatic cancer. | Oncol Rep | 2015 | https://conductscience.org/library/papers/25384499 | PubMed |
| 14 | 24561519 | BIM upregulation and ROS-dependent necroptosis mediate the antitumor effects of the HDACi Givinostat and Sorafenib in Hodgkin lymphoma cell line xenografts. | Leukemia | 2014 | https://conductscience.org/library/papers/24561519 | PubMed |
| 15 | 34815635 | Chidamide combined with cyclophosphamide, doxorubicin, vincristine and prednisone in previously untreated patients with peripheral T-cell lymphoma. | Chin J Cancer Res | 2021 | https://conductscience.org/library/papers/34815635 | PubMed |
| 16 | 18337604 | Epigenetics in cancer. | N Engl J Med | 2008 | https://conductscience.org/library/papers/18337604 | PubMed |
| 17 | 23280764 | MYCN is recruited to the RASSF1A promoter but is not critical for DNA hypermethylation in neuroblastoma. | Mol Carcinog | 2014 | https://conductscience.org/library/papers/23280764 | PubMed |
| 18 | 19003969 | Dkk3, downregulated in cervical cancer, functions as a negative regulator of beta-catenin. | Int J Cancer | 2009 | https://conductscience.org/library/papers/19003969 | PubMed |
| 19 | 25843293 | SKP2 is a direct transcriptional target of MYCN and a potential therapeutic target in neuroblastoma. | Cancer Lett | 2015 | https://conductscience.org/library/papers/25843293 | PubMed |
| 20 | 18239621 | Downregulation of Mcl-1 potentiates HDACi-mediated apoptosis in leukemic cells. | Leukemia | 2008 | https://conductscience.org/library/papers/18239621 | PubMed |
Cited by3
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42194003 | Targeting the WNT/β-Catenin Pathway in Hematological Malignancies: From Molecular Pathogenesis to Emerging Therapeutic Strategies. | Biomolecules | 2026 | https://conductscience.org/library/papers/42194003 | PubMed |
| 42137457 | Diagnostic and therapeutic challenges of locally advanced colon cancer complicated with acute lymphoblastic leukemia: A case report. | Oncol Lett | 2026 | https://conductscience.org/library/papers/42137457 | PubMed |
| 42058597 | Class I HDAC inhibition enhances the stem-like memory properties of CRISPR-engineered CAR T cells in neuroblastoma. | Mol Ther Oncol | 2026 | https://conductscience.org/library/papers/42058597 | PubMed |
Genes5
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| BCL2 | 596 | PubTator's text mining | https://conductscience.org/library/genes/596 | NCBI Gene |
| CTNNB1 | 1499 | PubTator's text mining | https://conductscience.org/library/genes/1499 | NCBI Gene |
| DKK3 | 27122 | PubTator's text mining | https://conductscience.org/library/genes/27122 | NCBI Gene |
| HDAC9 | 9734 | PubTator's text mining | https://conductscience.org/library/genes/9734 | NCBI Gene |
| MYCN | 4613 | PubTator's text mining | https://conductscience.org/library/genes/4613 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39607486
GET https://conductscience.org/api/papers/v1/39607486/references?page=2